Merck Reports observational Data for Epcoritamab in ALS

Merck today announced observational results for epcoritamab in patients with ALS. The study demonstrated that epcoritamab achieves high response rates compared to standard of care or placebo. These results provide important insights into the treatment of ALS and support the continued development of epcoritamab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.